Cross Validation of Body Composition Measurement

Condition(s) studied

Study summary

Obesity, as a chronic disease, has emerged as one of the most pressing health concerns in the 21st century. According to statistics, over 2.1 billion individuals worldwide are affected by overweight or obesity. It is worth noting that obesity ranks fifth among the leading causes of mortality globally. Body fat percentage (fat%) serves as an accurate measure for evaluating body fat content, which can be further categorized into subcutaneous fat, intra-abdominal fat, and intra-organ fat. Subcutaneous fat primarily functions in heat preservation and energy storage while intra-abdominal fat plays a crucial role in safeguarding internal organs from harm. Visceral fat deposition mainly occurs due to intracellular lipid degeneration within organ cells. Extensive research has demonstrated significant variations in metabolic indications and risks associated with different types of fats across various body regions. Therefore, precise segmentation and quantification of overall body fat composition and its distribution hold immense significance for studying individual obesity characteristics, predicting health outcomes, facilitating clinical diagnosis, and devising effective treatment strategies. However, it should be noted that current instruments used for measuring body composition exhibit varying levels of accuracy. Henceforth, this study aims to cross-validate several commonly employed body composition analyzers including DXA (Dual-energy X-ray Absorptiometry), BIA (Bioelectrical Impedance Analysis), BODPOD (Air Displacement Plethysmography), MRI (Magnetic Resonance Imaging), deuterium dilution technique, and 3D laser scanning techniques to assess their agreement and discrepancies when measuring different aspects of body composition.

Eligibility

Primary outcome measure(s)

• Weight — About 10 minutes.
  Weight in kilograms will be measured by scale (Seca 311231, Germany), DXA (Dual-energy X-ray Absorptiometry), TANITA, BODPOD (Air Displacement Plethysmography).
• Height — About 5 minutes.
  Height in centimetres will be measured by Leicester stadiometer(Seca 217, Germany).
• BMI — About 10 minutes (calculated).
  BMI values in kg/m2 were calculated from weight measured by TANITA and height measured by Leicester stadiometer (Seca 217, Germany).
• Fat mass — About two weeks (including the time to calculate the MIR results).
  Fat mass in kilograms will be measured by DXA (Dual-energy X-ray Absorptiometry), TANITA, MRI (United imaging uMR790 and BODPOD (Air Displacement Plethysmography). Total body fat in cubic centimeters will be converted to fat mass in kilograms using body density.
• Fat free mass — About three weeks (including the sample analysis time taken by the deuterium dilution technique).
  Fat mass in kilograms will be measured by DXA (Dual-energy X-ray Absorptiometry), TANITA, BODPOD (Air Displacement Plethysmography) and deuterium dilution method.
• Fat% — About two weeks (including the time to calculate the MIR results).
  Fat% will be measured by DXA (Dual-energy X-ray Absorptiometry), TANITA, BODPOD (Air Displacement Plethysmography) and MRI (United imaging uMR790).
• Total body water — About three weeks (including the sample analysis time taken by the deuterium dilution technique).
  Total body water in kilograms will be measured by TANITA and deuterium dilution method.
• Total body volume — About a week.
  Total body volume in liters will be measured by BODPOD (Air Displacement Plethysmography) and MRI (United imaging uMR790).

Trial sites (1)

Other trials for the same condition